|
Commercial
Scale
Antitubercular
Pyrazinamide
Isoniazid
Antimalarial
Artesunate
Arteether
Artemether
Dihydroartemisinin
Lumefantrine
Macrolides
Azithromycin
Erythromycin base
Erythromycin estolate
Erythromycin ethylsuccinate
Erythromycin oxime (intermediate)
Erythromycin stearate
Antihypertensive
Irbesartan
Lisinopril dihydrate
Losartan potassium
Antiepileptic
Valproic acid
Antiosteoporotic
Alendronate sodium
Zoledronic acid
Sedative, Hypnotic
Zopiclone
Antidepressant
Venlafaxine hydrochloride
Antihistaminic
Cetirizine dihydrochloride
Meclizine dihydrochloride
Hydroxyzine dihydrochloride
Pilot Plant Scale
Clarithromycin
Clopidogrel bisulphate
Divalproex sodium
Eprosartan
Eszopiclone
Sodium valproate
Valsartan
R & D Scale
Desvenlafaxine
Telmisartan
Development
Famciclovir
Ganciclovir
Levocetirizine
Piperaquine
Valganciclovir
Product
under patent offered only
for exempted research, clinical
and
development purposes.
Only non-
infringing products
and processes
are offered, subject to patent
status
verification by client.
|
| Development at Calyx R&D Centre |
Analytical Development:
Analytical Development Laboratory (ADL) at Calyx has contributed to the success of our API Development & CRAMS business. The analytical team has developed novel methods for resolution of positional isomers and difficult to resolve enantiomers using Chiral columns. Residual solvent methods have been developed and validated for 0.1ppm detection limits.
Ion chromatographic methods for detection @ ppm level have been developed for cations like Na+, K+, NH4+, Li+, Ca2+, Mg2+; and anions like chlorate, chlorite, chloride; bromide, bromate, azide, fluoride, nitrite, nitrate & sulphate.
The 400 MHz NMR has been extensively used for structural elucidation of unknown compounds, reference standards & impurities prepared for API’s by employing 2D techniques like COSY, NOSY, HETCOR, HMBC & HMQC.
Due to the strong analytical support Calyx has filed over seven DMF’s with US-FDA, two DMF’s with Health Canada, two CEP dossiers with EDQM and seventeen patents in the last two years.
Kilo Lab :
Calyx Kilo Lab actively pursuit scale-up of CRAMS and API. With the emphasis on Safety, Environment, Productivity and Cost Effectiveness, the Team has a right blend of Chemists and Chemical Engineers to churn out innovative methods. Several challenging CRAMS & API projects have been successfully scaled-up and commercialized. Multiple steps process have been successfully made ‘one-pot’ through telescoping. Calyx is actively working on Green Chemistry.
|
Business Development and Sales |
Business activities in South East Asia, Far East Countries including Japan
The Fourth quarter in last financial year (April08 to March09) was encouraging with growth in sales volumes, the launching of new products and the development of new customers and territories.
By the end of this quarter, we exported our leading APIs to South East Asian countries namely, Vietnam, Thailand, Philippines, Indonesia and Taiwan. We developed new customers in South Korea and Vietnam for our flagship products. Our exports of Erythromycin salts to Sri Lanka have been overwhelming. We bagged all bids floated by Sri Lankan Government. We have introduced Losartan Potassium and Clarithromycin in Sri Lanka. Customer feed back on satisfaction of our services and products, from this region, is very encouraging. We have introduced following new products into this territory. They are namely; Meclizine dihydrochloride, Cetrizine dihydrochloride and Hydroxyzine dihydrochloride.
In this quarter, we dispatched a couple of prestigious consignments of intermediates for APIs to Japan, giving a positive boom to our exports. Quite a few Japanese pharmaceutical companies are showing their interest in our CRAM activities. |
|
|
Safety, Environment and Quality Initiatives
|
38th National Safety Week Celebration at Calyx
The 38th National Safety Week was celebrated at Calyx during 4th – 10th March 09. Activities were planned across all divisions of Calyx for spearheading the objectives set by National Safety Council; the objective for achieving an overall goal of creating and strengthening SHE culture in workplace.
The theme of the Indian National Safety Council this year was "Take safety to all employees - whether organized or unorganized”. The inaugural function began with administration of the safety pledge. Our senior management team participated and addressed the gathering elaborating on the theme and emphasing the importance of safety in today’s business world.
During the week various activities were planned :
- Competitions on safety -slogans, posters, quiz and essay,
- Screening of safety films / videos
- Inter-departmental house keeping contest
- Lectures on safety & health
- Mock drills
Tarapur Industry Manufacturer Association (TIMA) had organized various competitions including “Fire Lady Award” to encourage women’s participation in Fire Fighting. Calyxians Ms. Pankaja Dalvi & Ms. Aparna Lingarkar received award during the fire fighting competition!
Valedictory function was arranged on 10th March 2009, where winners were given prizes and certificates.
Lost time accident-free man hours worked till March, 2009 :
Plant - 2.22 million (1st Jan,2004 onwards)
R&D - 0.61 million (1st June, 2007 onwards)
|
Pharmaceutical Leadership Summit – 2009 |
The Summit organized by the New Indian Express Group was held on 3rd April 2009 at Mumbai. The theme of the Summit was “Destination India – Challenges & Opportunities”. 40 leaders from the Pharmaceutical industry have shared their views during the Conference.
Dr Bansi Lal, our President-R&D was a speaker at one of the Plenary Sessions and he spoke on “New Chemical Entities – Challenges & Opportunities”. His session was well appreciated by the participants.
|
|
Disclaimer:
"The information in this e-mail and any attachments is confidential
and may be legally privileged. It is intended solely for the addressee
or addressees. If you are not an intended recipient, please delete
the message and any attachments and notify the
sender of misdelivery. Any use or disclosure of the
contents of either is unauthorized and may be
unlawful. All liability for viruses is excluded to the
fullest extent permitted by law. Any views expressed
in this message are those of the individual sender, except
where the sender states them, with requisite authority, to be those
of the specific Calyx company." |
India
Operations: Mr. Jitendra Shah : +91-251-2438310 ext: 520
jitendra_shah@calyxindia.com
Europe Operations: Mr. Prashant Ogale : +91-251-2438310
ext: 585 prashant_ogale@calyxindia.com
US Operations: Mr. Bharat K. Shah : +1-860-6910186
bharat.k.shah@calyxusa.com
Japan Operations: Dr. Sanjeev Gupte : +91-251-2438310
sanjeev_gupte@calyxindia.com
|
Calyx
Chemicals & Pharmaceuticals Ltd. |
|
Regd.
Office: Unit No.2 Marwah's Complex, Marwaha Estate, SakiVihar
Road, Andheri (E),
Mumbai - 400072, India Tel: +91-22-28031500, Fax: +91-22-66466817
Corp Office: A 37-38 MIDC -Phase -1, Golavli Kalyan
Shil Road, Dombivili (E) Dist. Thane 421203,
IndiaTel
: +91-251-2438310 Fax: +91-2512438726
New Jersey: Tel: +1-732-579-8569, Fax: +1-732-321-6562
Los Angeles: +1-213-219-7773, Fax: +1-775-514-1230,
Connecticut: Tel: +1-860-910-4279, Fax: +1-860-908-3177
Email: pharmanews@calyxindia.com URL:
www.calyxindia.com |
|
|
|
2009/25-CPN |
|
